Adherence to cholinesterase inhibitors in Alzheimer's Disease: A review

Dementia and Geriatric Cognitive Disorders

Volumn 35, Issue 5-6, 2013, Pages 351-363

  Brady, Roseanna ^a   Weinman, John ^b  

^a Atlantis Health Care   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Medication adherence; Medication non adherence; Medication persistence

Indexed keywords

CHOLINESTERASE INHIBITOR; ANTIDEPRESSANT AGENT; DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE;

ALZHEIMER DISEASE; CAREGIVER; CAREGIVER BURDEN; DRUG DELIVERY SYSTEM; DRUG TOLERABILITY; HUMAN; MEDICATION COMPLIANCE; PATIENT ATTITUDE; PATIENT CARE; PATIENT EDUCATION; PRIORITY JOURNAL; REVIEW; TREATMENT REFUSAL; ATTITUDE; BIBLIOGRAPHIC DATABASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HEALTH BELIEF; HEALTH EDUCATION; HOME MONITORING; MEDICATION THERAPY MANAGEMENT; MEDLINE; PATIENT COMPLIANCE; PHARMACY; PRESCRIPTION; QUALITY OF LIFE; REMINDER SYSTEM; RISK FACTOR;

ALZHEIMER DISEASE; ATTITUDE; ATTITUDE OF HEALTH PERSONNEL; CAREGIVERS; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS AS TOPIC; CULTURE; DISEASE PROGRESSION; DRUG PRESCRIPTIONS; HUMANS; NOOTROPIC AGENTS; PATIENT COMPLIANCE; QUALITY OF LIFE; RETROSPECTIVE STUDIES;

EID: 84876806579     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000347140     Document Type: Review

References (60)

1. The National Collaborating Centre for Primary Care (2009) Medicines adherence: Involving patients in decisions about prescribed medicines and supporting adherence. http://www.nice.org.uk/nicemedia/live/11766/42971/42971. pdf (accessed December 15, 2011
2. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X: Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008;CD000011
3. Reitz C, Brayne C, Mayeux R: Epidemiology of Alzheimer disease. Nat Rev Neurol 2011; 7: 137-152
4. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E: Alzheimer's disease. Lancet 2011; 377: 1019-1031
5. Massoud F, Gauthier S: Update on the pharmacological treatment of Alzheimer's disease. Curr Neuropharmacol 2010; 8: 69-80
6. Farlow MR, Miller ML, Pejovic V: Treatment options in Alzheimer's disease: Maximizing benefit, managing expectations. Dement Geriatr Cogn Disord 2008; 25: 408-422
7. Birks J: Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2009;CD005593
8. Small G, Dubois B: A review of compliance to treatment in Alzheimer's disease: Potential benefits of a transdermal patch. Curr Med Res Opin 2007; 23: 2705-2713
9. Lyle S, Grizzell M, Willmott S, Benbow S, Clark M, Jolley D: Treatment of a whole population sample of Alzheimer's disease with donepezil over a 4-year period: Lessons learned. Dement Geriatr Cogn Disord 2008; 25: 226-231
10. Birks J, Harvey RJ: Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2006;CD001190
11. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE: Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2009;CD001191
12. Loy C, Schneider L: Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev 2006;CD001747
13. Grossberg GT: Impact of rivastigmine on caregiver burden associated with Alzheimer's disease in both informal care and nursing home settings. Drugs Aging 2008; 25: 573-584
14. Molinuevo JL, Hernandez B: Profile of the informal carer associated with the clinical management of the Alzheimer's disease patient refractory to symptomatic treatment of the disease. Neurologia 2011; 26: 518-527
15. Howe E: Improving the quality of life in patients with Alzheimer's disease. Psychiatry (Edgmont) 2008; 5: 51-56
16. Beinart N, Weinman J, Wade D, Brady R: Caregiver burden and psychoeducational interventions in Alzheimer's disease: A review. Dement Geriatr Cogn Disord Extra 2012; 2: 638-648
17. Helzner EP, Scarmeas N, Cosentino S, Tang MX, Schupf N, Stern Y: Survival in Alzheimer disease: A multiethnic, population-based study of incident cases. Neurology 2008; 71: 1489-1495
18. Gillette-Guyonnet S, Andrieu S, Cortes F, Nourhashemi F, Cantet C, Ousset PJ, Reynish E, Grandjean H, Vellas B: Outcome of Alzheimer's disease: Potential impact of cholinesterase inhibitors. J Gerontol A Biol Sci Med Sci 2006; 61: 516-520
19. Wolstenholme J, Fenn P, Gray A, Keene J, Jacoby R, Hope T: Estimating the relationship between disease progression and cost of care in dementia. Br J Psychiatry 2002; 181: 36-42
20. Hill J, Fillit H, Thomas SK, Chang S: Functional impairment, healthcare costs and the prevalence of institutionalisation in patients with Alzheimer's disease and other dementias. Pharmacoeconomics 2006; 24: 265-280
21. Borah B, Sacco P, Zarotsky V: Predictors of adherence among Alzheimer's disease patients receiving oral therapy. Curr Med Res Opin 2010; 26: 1957-1965
22. Amuah JE, Hogan DB, Eliasziw M, Supina A, Beck P, Downey W, Maxwell CJ: Persistence with cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer's disease. Pharmacoepidemiol Drug Saf 2010; 19: 670-679
23. Blais L, Kettani FZ, Perreault S, Leroux JC, Forget A, Kergoat MJ: Adherence to cholinesterase inhibitors in patients with Alzheimer's disease. J Am Geriatr Soc 2009; 57: 366-368
24. Gadzhanova S, Roughead L, Mackson J: Anticholinesterase duration in the Australian veteran population. Aust NZ J Psychiatry 2010; 44: 469-474
25. Herrmann N, Binder C, Dalziel W, Smyth S, Camacho F: Persistence with cholinesterase inhibitor therapy for dementia: An observational administrative health database study. Drugs Aging 2009; 26: 403-407
26. Kroger E, van Marum R, Souverein P, Egberts T: Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: A retrospective cohort study. Drugs Aging 2010; 27: 663-675
27. Massoud F, Dorais M, Charbonneau C, Lescrauwaet B, Boucher JM, LeLorier J: Drug utilization review of cholinesterase inhibitors in Quebec. Can J Neurol Sci 2008; 35: 508-509
28. Mucha L, Shaohung S, Cuffel B, McRae T, Mark TL, Del Valle M: Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease. J Manag Care Pharm 2008; 14: 451-461
29. Pariente A, Pinet M, Moride Y, Merliere Y, Moore N, Fourrier-Reglat A: Factors associated with persistence of cholinesterase inhibitor treatments in the elderly. Pharmacoepidemiol Drug Saf 2010; 19: 680-686
30. Roe CM, Anderson MJ, Spivack B: How many patients complete an adequate trial of donepezil? Alzheimer Dis Assoc Disord 2002; 16: 49-51
31. Singh G, Thomas SK, Arcona S, Lingala V, Mithal A: Treatment persistency with rivastigmine and donepezil in a large state medicaid program. J Am Geriatr Soc 2005; 53: 1269-1270
32. Suh DC, Thomas SK, Valiyeva E, Arcona S, Vo L: Drug persistency of two cholinesterase inhibitors: Rivastigmine versus donepezil in elderly patients with Alzheimer's disease. Drugs Aging 2005; 22: 695-707
33. Schwalbe O, Scheerans C, Freiberg I, Schmidt-Pokrzywniak A, Stang A, Kloft C: Compliance assessment of ambulatory Alzheimer patients to aid therapeutic decisions by healthcare professionals. BMC Health Serv Res 2010; 10: 232
34. Harman G, Clare L: Illness representations and lived experience in early-stage dementia. Qual Health Res 2006; 16: 484-502
35. Clare L, Goater T, Woods B: Illness representations in early-stage dementia: A preliminary investigation. Int J Geriatr Psychiatry 2006; 21: 761-767
36. Roberts JS, Connell CM: Illness representations among first-degree relatives of people with Alzheimer disease. Alzheimer Dis Assoc Disord 2000; 14: 129-136; discussion 127-128
37. Banning M: Older people and adherence with medication: A review of the literature. Int J Nurs Stud 2008; 45: 1550-1561
38. Mukadam N, Cooper C, Livingston G: A systematic review of ethnicity and pathways to care in dementia. Int J Geriatr Psychiatry 2011; 26: 12-20
39. Gray HL, Jimenez DE, Cucciare MA, Tong HQ, Gallagher-Thompson D: Ethnic differences in beliefs regarding Alzheimer disease among dementia family caregivers. Am J Geriatr Psychiatry 2009; 17: 925-933
40. Molinuevo JL, Hernandez B: Assessment of the information provided by the medical specialist on Alzheimer's disease and that retained by the patient caregivers. Neurologia 2012; 27: 453-471
41. Massoud F, Belleville S, Bergman H, Kirk J, Chertkow H, Nasreddine Z, Joanette Y, Freedman M: Mild cognitive impairment and cognitive impairment, no dementia: Part B, therapy. Alzheimers Dement 2007; 3: 283-291
42. Cotrell V, Wild K, Bader T: Medication management and adherence among cognitively impaired older adults. J Gerontol Soc Work 2006; 47: 31-46
43. Beckman AG, Parker MG, Thorslund M: Can elderly people take their medicine? Patient Educ Couns 2005; 59: 186-191
44. Kairuz T, Bye L, Birdsall R, Deng T, Man L, Ross A, Samarasinha I, Tautolo E: Identifying compliance issues with prescription medicines among older people: A pilot study. Drugs Aging 2008; 25: 153-162
45. Tordoff JM, Bagge ML, Gray AR, Campbell AJ, Norris PT: Medicine-Taking practices in community-dwelling people aged > or =75 years in New Zealand. Age Ageing 2010; 39: 574-580
46. Corsonello A, Pedone C, Lattanzio F, Lucchetti M, Garasto S, Carbone C, Greco C, Fabbietti P, Incalzi RA: Regimen complexity and medication nonadherence in elderly patients. Ther Clin Risk Manag 2009; 5: 209-216
47. Bassil N, Grossberg GT: Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease. CNS Drugs 2009; 23: 293-307
48. Darreh-Shori T, Jelic V: Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia. Expert Opin Drug Saf 2010; 9: 167-176
49. Riepe MW, Ibach B: Neurological and psychiatric practitioners' views on Alzheimer's disease and treatment thereof. Dement Geriatr Cogn Disord 2008; 26: 541-546
50. Abetz L, Rofail D, Mertzanis P, Heelis R, Rosa K, Tellefsen C, Roborel de Climens A, McBurney C, Thomas S: Alzheimer's disease treatment: Assessing caregiver preferences for mode of treatment delivery. Adv Ther 2009; 26: 627-644
51. Blesa R, Ballard C, Orgogozo JM, Lane R, Thomas SK: Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease. Neurology 2007; 69:S23-S28
52. Winblad B, Kawata AK, Beusterien KM, Thomas SK, Wimo A, Lane R, Fillit H, Blesa R: Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry 2007; 22: 485-491
53. Mason A: New medicines in primary care: A review of influences on general practitioner prescribing. J Clin Pharm Ther 2008; 33: 1-10
54. Di Stefano A, Iannitelli A, Laserra S, Sozio P: Drug delivery strategies for Alzheimer's disease treatment. Expert Opin Drug Deliv 2011; 8: 581-603
55. Chan AL, Chien YW, Jin Lin S: Transdermal delivery of treatment for Alzheimer's disease: Development, clinical performance and future prospects. Drugs Aging 2008; 25: 761-775
56. Dhillon S: Rivastigmine transdermal patch: A review of its use in the management of dementia of the Alzheimer's type. Drugs 2011; 71: 1209-1231
57. Smith GE, Lunde AM, Hathaway JC, Vickers KS: Telehealth home monitoring of solitary persons with mild dementia. Am J Alzheimers Dis Other Demen 2007; 22: 20-26
58. O'Neill SA, Parente G, Donnelly MP, Nugent CD, Beattie MP, McClean SI, Scotney BW, Mason SC, Craig D: Assessing task compliance following mobile phone-based video reminders. Conf Proc IEEE Eng Med Biol Soc 2011; 2011: 5295-5298
59. Kamimura T, Ishiwata R, Inoue T: Medication reminder device for the elderly patients with mild cognitive impairment. Am J Alzheimers Dis Other Demen 2012; 27: 238-242
60. Gardette V, Andrieu S, Lapeyre-Mestre M, Coley N, Cantet C, Ousset PJ, Grand A, Monstastruc JL, Vellas B: Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer's disease: A 2-year prospective, multicentre, cohort study. CNS Drugs 2010; 24: 431-442.